Omada Health (NASDAQ:OMDA) Stock Price Down 9.3% - Here's Why

Key Points

• Omada Health shares fell 9.3% on Friday, with trading volume running about 50% above average, suggesting heavy short-term selling pressure despite recent upbeat news.
• The company posted a Q1 earnings beat, reporting EPS of ($0.05) versus expectations of ($0.08) and revenue of $78.05 million, while also raising FY2026 revenue guidance to $322 million to $330 million.
• Wall Street sentiment remained generally constructive, with multiple firms raising price targets and maintaining buy-type ratings, and Omada also gaining a strategic boost by joining Eli Lilly’s Employer Connect program to expand access for its GLP-1 Care Track.

Shares of Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) fell 9.3% on Friday . The stock traded as low as $14.94 and last traded at $14.8730. 1,825,262 shares traded hands during mid-day trading, an increase of 50% from the average session volume of 1,218,513 shares. The stock had previously closed at $16.40.

Key Headlines Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Multiple brokerages raised price targets or reiterated buy ratings (signals of analyst confidence and potential upside). Barclays raised its PT to $20 (overweight). Benzinga
• Positive Sentiment: Citizens Jmp raised its target to $21 (market outperform), implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Needham reaffirmed a "buy" rating with a $28 target, the most bullish analyst view published today and supportive of a long‑term growth narrative. Benzinga
• Positive Sentiment: Omada will serve as an independent program administrator in Eli Lilly’s Employer Connect program, expanding access for its GLP‑1 Care Track — a strategic business development that could drive future revenue growth. GlobeNewswire
• Positive Sentiment: Q1 results: EPS of ($0.05) beat the Street ($0.08) and revenue was $78.05M — a modest beat that supports near‑term execution credibility. Press Release / Slide Deck
• Neutral Sentiment: Wells Fargo nudged its target to $18 but kept an "equal weight" rating — a mixed signal that reduces the uniformity of bullish analyst views. Benzinga The Fly
• Neutral Sentiment: FY2026 revenue guidance was raised to $322–$330M versus a $319.1M consensus — a modest beat that supports revenue momentum but isn't a large surprise. The company’s EPS guidance was not clearly specified in the release, which may leave some uncertainty around near‑term profitability expectations. Slide Deck
• Neutral Sentiment: For detail and color on management comments, see the Q1 earnings call transcript and analyst metric breakdowns — useful for investors assessing guidance cadence and margin trajectory. Earnings Call Transcript Zacks analysis
• Negative Sentiment: Despite the positives, shares are trading lower with above‑average volume — indicating short‑term selling pressure or profit‑taking. That suggests investors are weighing valuation, execution risks, or the lack of clearer EPS guidance. MarketBeat

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Omada Health from a "hold" rating to a "buy" rating in a report on Saturday, March 14th. Canaccord Genuity Group set a $24.00 price objective on shares of Omada Health in a research report on Friday. Wells Fargo & Company boosted their target price on shares of Omada Health from $17.00 to $18.00 and gave the stock an "equal weight" rating in a report on Friday. Barclays increased their target price on shares of Omada Health from $18.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday. Finally, Morgan Stanley decreased their price target on shares of Omada Health from $32.00 to $30.00 and set an "overweight" rating on the stock in a research report on Friday, March 6th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Omada Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $22.91.

Omada Health Trading Down 10.4%

The stock has a 50-day moving average of $13.55 and a two-hundred day moving average of $15.85. The firm has a market cap of $872.88 million and a price-to-earnings ratio of -86.34.

Omada Health (NASDAQ:OMDA - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. The company had revenue of $78.05 million for the quarter. Sell-side analysts expect that Omada Health, Inc. will post -0.04 EPS for the current fiscal year.

Insider Activity at Omada Health

In other Omada Health news, President Wei-Li Shao sold 2,829 shares of the business's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $12.71, for a total transaction of $35,956.59. Following the sale, the president directly owned 328,850 shares of the company's stock, valued at $4,179,683.50. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Steven L. Cook sold 1,884 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $13.94, for a total value of $26,262.96. Following the completion of the sale, the chief financial officer owned 200,512 shares of the company's stock, valued at $2,795,137.28. The trade was a 0.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 8,776 shares of company stock worth $120,483.

Institutional Investors Weigh In On Omada Health

Hedge funds have recently bought and sold shares of the business. BIT Capital GmbH purchased a new stake in shares of Omada Health in the third quarter worth approximately $13,639,000. Divisadero Street Capital Management LP purchased a new position in Omada Health during the third quarter valued at approximately $30,510,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Omada Health in the 4th quarter valued at approximately $1,222,000. Tudor Investment Corp ET AL purchased a new stake in Omada Health in the 3rd quarter worth approximately $987,000. Finally, Fortress Investment Group LLC boosted its stake in shares of Omada Health by 43.1% during the 3rd quarter. Fortress Investment Group LLC now owns 225,000 shares of the company's stock valued at $4,975,000 after buying an additional 67,750 shares during the period.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.